Publications
(2026) Benzoxaborole-modified azithromycins inhibit translation without inducing expression. Antimicrob Agents Chemother. 10.1128/aac.01539-25
(2026) Benzoxaborole-modified azithromycins inhibit translation without inducing expression. Antimicrob Agents Chemother. 10.1128/aac.01539-25
(2026) Benzoxaborole-modified azithromycins inhibit translation without inducing expression. Antimicrob Agents Chemother. 10.1128/aac.01539-25
(2026) Benzoxaborole-modified azithromycins inhibit translation without inducing expression. Antimicrob Agents Chemother. 10.1128/aac.01539-25
(2026) Benzoxaborole-modified azithromycins inhibit translation without inducing expression. Antimicrob Agents Chemother. 10.1128/aac.01539-25
(2026) Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C. J Med Chem. 69, 5241-5258
(2026) Quantification and transcriptome profiling reveal abundant, dynamic and translatable dephospho-CoA-capped RNAs. Nat Biotechnol. 10.1038/s41587-026-03040-4
(2026) Serendipitous Discovery of an Allosteric Inhibitor Binding Groove in the Proline Biosynthetic Enzyme Pyrroline-5-Carboxylate Reductase 1 (PYCR1). Biochem J. 10.1042/BCJ20250278
(2026) Serendipitous Discovery of an Allosteric Inhibitor Binding Groove in the Proline Biosynthetic Enzyme Pyrroline-5-Carboxylate Reductase 1 (PYCR1). Biochem J. 10.1042/BCJ20250278
(2026) Small-molecule binding and sensing with a designed protein family. Nat Commun. 10.1038/s41467-026-70953-8
(2026) Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivo. Protein Sci. 35, e70462
(2026) Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivo. Protein Sci. 35, e70462
(2025) Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain. Eur J Med Chem. 302, 118274
(2025) BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.. Science. 10.1126/science.adq2004
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Binding of small molecules at the P-stalk site of ricin A subunit trigger conformational changes that extend into the active site. J Biol Chem. 10.1016/j.jbc.2025.108310
(2025) Binding of small molecules at the P-stalk site of ricin A subunit trigger conformational changes that extend into the active site. J Biol Chem. 10.1016/j.jbc.2025.108310
(2025) A broad-spectrum lasso peptide antibiotic targeting the bacterial ribosome. Nature. 10.1038/s41586-025-08723-7
(2025) A broad-spectrum lasso peptide antibiotic targeting the bacterial ribosome. Nature. 10.1038/s41586-025-08723-7
(2025) Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions. J Biol Chem. 10.1016/j.jbc.2025.108348

